Wedbush Issues Pessimistic Forecast for ACRS Earnings

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) – Equities researchers at Wedbush reduced their FY2025 earnings estimates for Aclaris Therapeutics in a research report issued on Thursday, November 6th. Wedbush analyst M. Fan now expects that the biotechnology company will post earnings per share of ($0.51) for the year, down from their prior estimate of ($0.50). The consensus estimate for Aclaris Therapeutics’ current full-year earnings is ($0.82) per share. Wedbush also issued estimates for Aclaris Therapeutics’ Q4 2025 earnings at ($0.14) EPS and FY2029 earnings at ($0.43) EPS.

Several other equities analysts also recently weighed in on ACRS. HC Wainwright restated a “buy” rating and set a $16.00 price target on shares of Aclaris Therapeutics in a report on Monday, October 20th. Weiss Ratings reissued a “sell (d-)” rating on shares of Aclaris Therapeutics in a research report on Wednesday. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Aclaris Therapeutics has an average rating of “Moderate Buy” and an average target price of $8.71.

Aclaris Therapeutics Trading Up 2.2%

Shares of NASDAQ:ACRS opened at $2.32 on Monday. The stock has a fifty day simple moving average of $2.05 and a two-hundred day simple moving average of $1.70. Aclaris Therapeutics has a 12-month low of $1.05 and a 12-month high of $5.17. The stock has a market capitalization of $251.33 million, a price-to-earnings ratio of -1.69 and a beta of 0.43.

Aclaris Therapeutics (NASDAQ:ACRS) last posted its quarterly earnings results on Thursday, November 6th. The biotechnology company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.01. Aclaris Therapeutics had a negative return on equity of 34.01% and a negative net margin of 802.03%.The company had revenue of $3.30 million for the quarter, compared to the consensus estimate of $1.59 million.

Institutional Investors Weigh In On Aclaris Therapeutics

A number of large investors have recently added to or reduced their stakes in the stock. Millennium Management LLC raised its stake in Aclaris Therapeutics by 111.0% during the 1st quarter. Millennium Management LLC now owns 4,134,148 shares of the biotechnology company’s stock valued at $6,325,000 after buying an additional 2,175,101 shares during the last quarter. Decheng Capital LLC grew its holdings in shares of Aclaris Therapeutics by 78.3% in the first quarter. Decheng Capital LLC now owns 4,041,736 shares of the biotechnology company’s stock worth $6,184,000 after acquiring an additional 1,775,069 shares during the period. Geode Capital Management LLC increased its position in Aclaris Therapeutics by 108.4% during the second quarter. Geode Capital Management LLC now owns 2,464,779 shares of the biotechnology company’s stock valued at $3,501,000 after acquiring an additional 1,282,042 shares during the last quarter. Acadian Asset Management LLC increased its position in Aclaris Therapeutics by 10.9% during the second quarter. Acadian Asset Management LLC now owns 2,433,850 shares of the biotechnology company’s stock valued at $3,453,000 after acquiring an additional 238,659 shares during the last quarter. Finally, Palo Alto Investors LP lifted its holdings in Aclaris Therapeutics by 36.2% in the first quarter. Palo Alto Investors LP now owns 776,028 shares of the biotechnology company’s stock valued at $1,187,000 after acquiring an additional 206,196 shares during the period. Institutional investors own 98.34% of the company’s stock.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.